REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 201 filers reported holding REATA PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 2.11 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $72,712,774 | +26.4% | 713,150 | +12.7% | 0.00% | +33.3% |
| Q1 2023 | $57,547,267 | +10.6% | 632,945 | -53.8% | 0.00% | +50.0% |
| Q4 2022 | $52,045,692 | +175.7% | 1,369,984 | +82.4% | 0.00% | +100.0% |
| Q3 2022 | $18,879,000 | -16.2% | 751,243 | +1.3% | 0.00% | 0.0% |
| Q2 2022 | $22,541,000 | +3.0% | 741,713 | +11.0% | 0.00% | 0.0% |
| Q1 2022 | $21,884,000 | +24.1% | 668,018 | -0.1% | 0.00% | 0.0% |
| Q4 2021 | $17,631,000 | -71.9% | 668,614 | +7.2% | 0.00% | -66.7% |
| Q3 2021 | $62,776,000 | -24.8% | 623,956 | +5.8% | 0.00% | -25.0% |
| Q2 2021 | $83,430,000 | +120.0% | 589,489 | +55.0% | 0.00% | +100.0% |
| Q1 2021 | $37,925,000 | -20.0% | 380,389 | -0.7% | 0.00% | -33.3% |
| Q4 2020 | $47,378,000 | +25.6% | 383,259 | -1.0% | 0.00% | 0.0% |
| Q3 2020 | $37,729,000 | -33.1% | 387,282 | +7.2% | 0.00% | -25.0% |
| Q2 2020 | $56,366,000 | -24.6% | 361,277 | -30.3% | 0.00% | -42.9% |
| Q1 2020 | $74,792,000 | -28.4% | 518,165 | +1.4% | 0.01% | 0.0% |
| Q4 2019 | $104,417,000 | +179.8% | 510,771 | +9.9% | 0.01% | +133.3% |
| Q3 2019 | $37,316,000 | -13.7% | 464,768 | +1.5% | 0.00% | 0.0% |
| Q2 2019 | $43,216,000 | +18.9% | 458,040 | +7.7% | 0.00% | 0.0% |
| Q1 2019 | $36,355,000 | +45.6% | 425,357 | -4.4% | 0.00% | +50.0% |
| Q4 2018 | $24,971,000 | -25.0% | 445,120 | +9.3% | 0.00% | -33.3% |
| Q3 2018 | $33,286,000 | +200.1% | 407,102 | +28.3% | 0.00% | +200.0% |
| Q2 2018 | $11,092,000 | +189.8% | 317,211 | +70.0% | 0.00% | – |
| Q1 2018 | $3,828,000 | -24.1% | 186,597 | +4.8% | 0.00% | – |
| Q4 2017 | $5,041,000 | +13.8% | 177,968 | +24.9% | 0.00% | – |
| Q3 2017 | $4,428,000 | +29.4% | 142,447 | +31.6% | 0.00% | – |
| Q2 2017 | $3,422,000 | +46.3% | 108,212 | +4.9% | 0.00% | – |
| Q1 2017 | $2,339,000 | +6.8% | 103,118 | +2.7% | 0.00% | – |
| Q4 2016 | $2,191,000 | -13.0% | 100,414 | +5.1% | 0.00% | – |
| Q3 2016 | $2,517,000 | +100.9% | 95,535 | +50.7% | 0.00% | – |
| Q2 2016 | $1,253,000 | – | 63,411 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 245,000 | $13,745,000 | 18.25% |
| CPMG Inc | 3,023,349 | $169,610,000 | 15.00% |
| Prosight Management, LP | 253,000 | $14,193,000 | 7.33% |
| Cormorant Asset Management, LP | 674,251 | $37,825,000 | 3.07% |
| LBJ Family Wealth Advisors, Ltd. | 53,404 | $2,996,000 | 2.63% |
| P.A.W. CAPITAL CORP | 25,000 | $1,403,000 | 1.76% |
| MORGENS WATERFALL VINTIADIS & CO INC | 32,000 | $1,795,000 | 1.60% |
| SPHERA FUNDS MANAGEMENT LTD. | 221,269 | $12,413,000 | 1.40% |
| EMERALD ADVISERS, LLC | 470,431 | $26,391,000 | 1.30% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 486,210 | $27,276,000 | 1.28% |